Gastrointestinal tract function modulation

"Gastrointestinal tract function modulation" is a broad therapeutic aim referring to the alteration of the physiological functions of the gastrointestinal (GI) tract, such as motility, secretion, barrier integrity, immune response, and absorption. This modulation can occur through various molecular targets including gut neurotransmitter receptors (e.g., serotonin receptors), ion channels, transporters (e.g., GLUT9, ABCG2, URAT1), intracellular signaling molecules, and the gut microbiota. Agents developed for this purpose may act by stimulating or inhibiting contractions (like giant migrating contractions), altering transporter activity, releasing endogenous mediators (NO, H2S, CO), or modulating gut microbial composition and mucosal immunity. Diseases relevant to this modulation include constipation, IBS, bowel dysfunction, and GI cancers like GIST, each associated with specific drug targets. Safety concerns are mostly related to the risk of excessive stimulation (e.g., diarrhea, cramping), toxicity (e.g., GI damage from drugs), and unintended disruption of homeostatic functions or microbial balance. In summary, "Gastrointestinal tract function modulation" is not itself a molecule, receptor, or gene, but encompasses a variety of molecular targets and physiological mechanisms in GI medicine and pharmacology.

Other names

Gut motility modulationGastrointestinal motility regulationGI transit modulation

Modulation of enteric serotonin signaling (via 5-HT receptors), Stimulation or inhibition of colonic giant migrating contractions (GMCs), Modulation of gut transporters (GLUT9, ABCG2, URAT1), Release of endogenous gaseous mediators (NO, H2S, CO), Alteration of gut microbiota and mucosal barrier, Inhibition of receptor tyrosine kinases (e.g., KIT in GIST)